The effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first-degree relatives of patients with depression-A randomised trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
The effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first-degree relatives of patients with depression-A randomised trial. / Knorr, Ulla; Vinberg, Maj; Gether, Ulrik; Winkel, Per; Gluud, Christian; Wetterslev, Jørn; Kessing, Lars Vedel.
I: Psychiatry Research Review, Bind 200, Nr. 2-3, 30.12.2012, s. 354-60.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first-degree relatives of patients with depression-A randomised trial
AU - Knorr, Ulla
AU - Vinberg, Maj
AU - Gether, Ulrik
AU - Winkel, Per
AU - Gluud, Christian
AU - Wetterslev, Jørn
AU - Kessing, Lars Vedel
N1 - Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
PY - 2012/12/30
Y1 - 2012/12/30
N2 - The effect of selective serotonin reuptake inhibitors (SSRI) on healthy individuals remains unclear. We tested the hypothesis that escitalopram decreases perceived stress and salivary cortisol. The trial has a randomised, blinded, placebo-controlled, parallel-group design. After informed consent 80 healthy first-degree relatives to patients with depression were randomly allocated to receive daily tablets of escitalopram 10mg or placebo for 4 weeks. The area under the curve (AUC) for awakening and all day salivary cortisol was analysed in samples taken immediately after awakening and at 15-min intervals for the next hour, and at 12:00, 18:00 and 23:00. The salivary cortisol awakening response, all day salivary cortisol, and scale scores on sleep, pain, aggression, quality of life, and perceived stress assessed at entry were compared to values following 4 weeks of intervention. Statistically significant decreases were found in awakening salivary cortisol (P=0.04) and in all day salivary cortisol (P=0.02) in the escitalopram group compared with the placebo group. There were no statistically significant differences in perceived stress between the intervention groups. These findings from a randomised clinical trial suggest that a long-term escitalopram administration to healthy participants results in a decrease in the hypothalamic-pituitary-adrenal (HPA) activity measured by salivary cortisol compared with inert placebo. However, change in salivary cortisol was one out of multiple outcome measures. The results of the present trial do not refute salivary cortisol as a potential endophenotype for depression.
AB - The effect of selective serotonin reuptake inhibitors (SSRI) on healthy individuals remains unclear. We tested the hypothesis that escitalopram decreases perceived stress and salivary cortisol. The trial has a randomised, blinded, placebo-controlled, parallel-group design. After informed consent 80 healthy first-degree relatives to patients with depression were randomly allocated to receive daily tablets of escitalopram 10mg or placebo for 4 weeks. The area under the curve (AUC) for awakening and all day salivary cortisol was analysed in samples taken immediately after awakening and at 15-min intervals for the next hour, and at 12:00, 18:00 and 23:00. The salivary cortisol awakening response, all day salivary cortisol, and scale scores on sleep, pain, aggression, quality of life, and perceived stress assessed at entry were compared to values following 4 weeks of intervention. Statistically significant decreases were found in awakening salivary cortisol (P=0.04) and in all day salivary cortisol (P=0.02) in the escitalopram group compared with the placebo group. There were no statistically significant differences in perceived stress between the intervention groups. These findings from a randomised clinical trial suggest that a long-term escitalopram administration to healthy participants results in a decrease in the hypothalamic-pituitary-adrenal (HPA) activity measured by salivary cortisol compared with inert placebo. However, change in salivary cortisol was one out of multiple outcome measures. The results of the present trial do not refute salivary cortisol as a potential endophenotype for depression.
KW - Adult
KW - Aggression
KW - Antidepressive Agents, Second-Generation
KW - Citalopram
KW - Depressive Disorder
KW - Family
KW - Female
KW - Humans
KW - Hydrocortisone
KW - Hypothalamo-Hypophyseal System
KW - Male
KW - Middle Aged
KW - Pituitary-Adrenal System
KW - Quality of Life
KW - Saliva
KW - Sleep
KW - Stress, Psychological
U2 - 10.1016/j.psychres.2012.05.015
DO - 10.1016/j.psychres.2012.05.015
M3 - Journal article
C2 - 22703642
VL - 200
SP - 354
EP - 360
JO - Psychiatry Research Review
JF - Psychiatry Research Review
SN - 1178-6183
IS - 2-3
ER -
ID: 47292657